Quest Diagnostics DGX recently launched its new laboratory blood test, AD-Detect Abeta, which combines 42/40 and p-tau217 Evaluation. It is designed to help physicians confirm amyloid brain pathology ...

The Spark is powered by Nvidia’s GB10 Blackwell Superchip, featuring a GPU with fifth-generation Tensor Cores and FP4 support ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

One impacted location is the DGX at the Sibley Building in downtown Rochester. “I just feel like people come downstairs to gather together and see each other,” said Amonti Stenson, a DGX employee.

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine ...

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...